Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology
- 94 Downloads
Histone deacetylases (HDACs) are expressed at increased levels in cells of various malignancies, and the use of HDAC inhibitors has improved outcomes in patients with haematological malignancies (T-cell lymphomas and multiple myeloma). However, they are not as effective in solid tumours. Five agents are currently approved under various jurisdictions, namely belinostat, chidamide, panobinostat, romidepsin and vorinostat. These agents are associated with a range of class-related and agent-specific serious and/or severe adverse effects, notably myelosuppression, diarrhoea and various cardiac effects. Among the cardiac effects are ST-T segment abnormalities and QTc interval prolongation of the electrocardiogram, isolated cases of atrial fibrillation and, in rare instances, ventricular tachyarrhythmias. In order to improve the safety profile of this class of drugs as well as their efficacy in indications already approved and to further widen their indications, a large number of newer HDAC inhibitors with varying degrees of HDAC isoform selectivity have been synthesised and are currently under clinical development. Preliminary evidence from early studies suggests that they may be effective in non-haematological cancers as well when used in combination with other therapeutic modalities, but that they too appear to be associated with the above class-related adverse effects. As the database accumulates, the safety, efficacy and risk/benefit of the newer agents and their indications will become clearer.
Compliance with Ethical Standards
This is a review of the data in the public domain and the author declares compliance with all ethical standards.
No sources of funding were used to assist in the preparation of this review.
Conflict of interest
Rashmi Shah has no conflicts of interest that are relevant to the content of this review and has not received any financial support for writing it. He was formerly a Senior Clinical Assessor at the Medicines and Healthcare products Regulatory Agency (MHRA), London, UK, and now provides expert consultancy services to a number of pharmaceutical companies.
- 11.Hayashi A, Horiuchi A, Kikuchi N, Hayashi T, Fuseya C, Suzuki A, et al. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin. Int J Cancer. 2010;127:1332–46.CrossRefGoogle Scholar
- 16.Food and Drug Administration. Drug-specific reviews on Drugs@FDA. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
- 17.European Medicines Agency. Drug-specific assessment reports and labels. Available at: https://www.ema.europa.eu/en/medicines/field_ema_web_categories%253Aname_field/Human/ema_group_types/ema_medicine.
- 18.European Medicines Agency. Vorinostat - withdrawal assessment report (EMEA/CHMP/559066/2008). Available at: https://www.ema.europa.eu/documents/withdrawal-report/withdrawal-assessment-report-vorinostat-msd_en.pdf.
- 19.European Medicines Agency. Refusal of the marketing authorisation for Istodax (romidepsin) (EMA/475603/2012). Available at: https://www.ema.europa.eu/documents/smop-initial/questions-answers-refusal-marketing-authorisation-istodax-romidepsin_en.pdf.
- 23.Sharma S, Witteveen PO, Lolkema MP, Hess D, Gelderblom H, Hussain SA, et al. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. Cancer Chemother Pharmacol. 2015;75:87–95.CrossRefGoogle Scholar
- 29.Food and Drug Administration. Label for FARYDAK (panobinostat) (23 February 2015). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf.
- 35.Fischer T, Patnaik A, Bhalla K, Beck J, Morganroth J, Laird GH, et al. Results of cardiac monitoring during phase I trials of a novel histone deacetylase (HDAC) inhibitor LBH589 in patients with advanced solid tumors and hematologic malignancies. J Clin Oncol. 2005;23(16_suppl):Abstract 3106.Google Scholar
- 50.Vey N, Prebet T, Thalamas C, Charbonnier A, Rey J, Kloos I, et al. Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia. Leuk Lymphoma. 2017;58:1880–6.CrossRefGoogle Scholar
- 53.Prebet T, Sun Z, Figueroa ME, Ketterling R, Melnick A, Greenberg PL, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. J Clin Oncol. 2014;32:1242–8.CrossRefGoogle Scholar
- 55.Younes A, Berdeja JG, Patel MR, Flinn I, Gerecitano JF, Neelapu SS, et al. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. Lancet Oncol. 2016;17:622–31.CrossRefGoogle Scholar
- 60.Venugopal B, Baird R, Kristeleit RS, Plummer R, Cowan R, Stewart A, et al. A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Clin Cancer Res. 2013;19:4262–72.CrossRefGoogle Scholar
- 66.Kopljar I, Gallacher DJ, De Bondt A, Cougnaud L, Vlaminckx E, Van den Wyngaert I, et al. Functional and transcriptional characterization of histone deacetylase inhibitor-mediated cardiac adverse effects in human induced pluripotent stem cell-derived cardiomyocytes. Stem Cells Transl Med. 2016;5:602–12.CrossRefGoogle Scholar